Hers vs Hims
Hers and Hims both sell semaglutide and tirzepatide; this is how their prices, coverage and records differ.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Hers
Best for: coverage in all 50 states, which most sellers will not confirm
Visit Hers →
Hims
Best for: knowing which pharmacy fills the vial: it names Apostrophe Pharmacy LLC
Visit Hims →If you are choosing between Hers and Hims, price alone will not settle it. Both prescribe semaglutide and tirzepatide, so moving from one to the other would not change your drug. Hers leads our six-part score, 7.0 to 6.8. One of the two has an FDA warning letter on record, covered below.
Hers vs Hims price
Hers and Hims start at the same figure, $199 a month, so the entry price does not separate them. Look at what each price covers and at the per-drug prices below.
Drug by drug: Semaglutide costs the same at both, $199 a month; tirzepatide costs the same at both, $299 a month.
Medications and formats
Both sell semaglutide and tirzepatide.
On format they match: each offers compounded injections and brand-name pens.
Where each one treats patients
Hers lists 50 states, and Hims lists 50 states.
They overlap in 50 states.
Pricing
Hers
Brand Zepbound from $299/mo medication-only; requires Hers Weight Loss Membership ($149/mo)
Hims
Brand Zepbound from $299/mo medication-only; requires Hims Weight Loss Membership ($149/mo)
What each price covers
Both prices cover the medication itself.
Hers is silent on shipping and lab work.
Hims is silent on shipping and lab work.
Hers
Covered by the monthly price
Medication
In the price
Clinician visits
Charged on top
Shipping
Not stated
Lab work
Not stated
Coaching
Charged on top
Hims
Covered by the monthly price
Medication
In the price
Clinician visits
Charged on top
Shipping
Not stated
Lab work
Not stated
Coaching
Charged on top
Where each one scores higher
Overall, Hers scores 7.0 and Hims 6.8 out of 10.
Hers is stronger on trust & safety (8.5 vs 7.0).
Value, effectiveness, user experience, accessibility and support are within half a point.
Hers
7.0/10
Hims
6.8/10
Value25%
Effectiveness25%
User Experience15%
Trust & Safety15%
Accessibility10%
Support10%
FDA warning letters
The FDA sent Hims a warning letter dated September 9, 2025 (letter 716567), and it is still open.
Hers has no FDA warning letter on record with us.
Features & Coverage
| Feature | Hers | Hims |
|---|---|---|
| Starting Price | $199/mo | $199/mo |
| Features | 2 features | 2 features |
| States Available | 50 | 50 |
| Compounded | ✓ Yes | ✓ Yes |
| Brand Name | ✓ Yes | ✓ Yes |
| FSA/HSA Accepted | — | — |
| FDA Warning Letters | ✓None | 1 letter |
About Hers
Hers is the women-focused telehealth brand from Hims and Hers. It sells compounded semaglutide on a 6-month plan.
Read our full Hers review →About Hims
Hims is a major men's telehealth brand. Its weight loss offering is compounded semaglutide on a 6-month plan.
Read our full Hims review →Pros & Cons
Hers
What we like
- Shows its price before the medical questionnaire, so you can compare it without handing over health information
- The monthly price includes the medication
- Serves all 50 states
- We found no FDA warning letters issued to Hers
Watch-outs
- Not included in the monthly price: clinician visits, coaching
- Ask which pharmacy fills the prescription before you pay, so you can check its license
- Its semaglutide is compounded rather than FDA-approved, so it has not been reviewed by the agency for safety, effectiveness or manufacturing quality
Hims
What we like
- Shows its price before the medical questionnaire, so you can compare it without handing over health information
- The monthly price includes the medication
- Serves all 50 states
- Names 4 pharmacies that fill its prescriptions, which most sellers do not
Watch-outs
- Not included in the monthly price: clinician visits, coaching
- The FDA has issued Hims a warning letter. Read what it alleges: a letter flags a problem but does not by itself rule a seller out
- Its semaglutide is compounded rather than FDA-approved, so it has not been reviewed by the agency for safety, effectiveness or manufacturing quality
Our Verdict
Hers wins this one, 7.0 to 6.8, above all for coverage in all 50 states, which most sellers will not confirm. Hims fits better if knowing which pharmacy fills the vial: it names Apostrophe Pharmacy LLC is your priority.
Choose Hers if…
You want coverage in all 50 states, which most sellers will not confirm and an opening price near $199 a month.
Choose Hims if…
You want knowing which pharmacy fills the vial: it names Apostrophe Pharmacy LLC and an opening price near $199 a month.
Ready to start? GLP-1 providers we have vetted
Telehealth providers, vetted by us, prescribing GLP-1 online.
Vetted by our editors · no insurance required
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
RNK Health
An oral route if you will not self-inject
From $197/mo
Get started →He & She MD
Starting below a standard dose, with microdose tiers
From $99/mo
Get started →Wellorithm
Compounded semaglutide at $247/month
From $247/mo
Get started →Hers vs Hims: FAQ
Close alternatives to Hers and Hims
- Hers vs Noom
- Hers vs Care Bare Rx
- Hers vs Concierge MD LA
- Hims vs Noom
- Hims vs Care Bare Rx
- Hims vs Concierge MD LA
Or see the full category ranking.
Novo Nordisk A/S owns the Wegovy®, Ozempic® and Rybelsus® marks; Eli Lilly and Company owns Mounjaro® and Zepbound®. Every other product name and mark on this page belongs to whoever owns it. No pharmaceutical manufacturer is affiliated with GLP Watchdog. See trademark disclaimer.